NAD+ (Nicotinamide Adenine Dinucleotide) has become one of the most discussed molecules in longevity medicine. IV clinics now offer NAD+ infusions at prices ranging from $300 to over $1,000 per session, and the supplement industry has built a billion-dollar market around its oral precursors NMN and NR. But what does the actual peer-reviewed evidence support — and where does the science end and the marketing begin?
This article works through the published literature methodically, separating what is well-established from what remains speculative.
The Biology: Why NAD+ Matters
NAD+ sits at the intersection of virtually every major metabolic process in the human body. As an electron carrier, it drives the cellular energy production that powers all living tissue. As a co-substrate for sirtuins and PARPs, it directly regulates gene expression, DNA repair, and stress response. Understanding why NAD+ declines with age — and what consequences that decline has — requires working through each of these roles carefully.
Cellular Energy Production
In the mitochondria, NAD+ accepts electrons from metabolic reactions, becoming NADH. NADH then donates those electrons to the electron transport chain, driving the production of ATP — the cell's energy currency. When NAD+ levels fall, this process becomes less efficient. Cells in energy-intensive tissues (muscle, brain, liver) are particularly vulnerable, and the resulting mitochondrial dysfunction is a hallmark of biological aging.
Sirtuin Activation
Sirtuins (SIRT1–SIRT7) are a family of enzymes that function as master regulators of the cellular stress response, metabolic adaptation, and longevity pathways. Crucially, they require NAD+ as a co-substrate to function — they do not merely use NAD+ as a fuel source; they consume it enzymatically. This means that declining NAD+ availability directly impairs sirtuin function, with downstream consequences including impaired DNA repair, reduced mitochondrial biogenesis, and compromised circadian rhythm regulation.
David Sinclair's laboratory at Harvard has produced some of the most widely cited work on this connection, demonstrating in animal models that restoring NAD+ levels can restore sirtuin activity and reverse several age-related phenotypes.
DNA Repair via PARP Enzymes
PARP (Poly ADP-Ribose Polymerase) enzymes detect and repair DNA strand breaks — a continuous process in all living cells. PARPs consume NAD+ as they work. In the context of aging, where DNA damage accumulates and PARP demand increases, this creates a vicious cycle: high DNA damage increases PARP activity, which depletes NAD+, which impairs sirtuins, which further compromises DNA repair. Breaking this cycle through NAD+ restoration is one of the central rationales for supplementation.
DNA repair is among the most energetically demanding processes in the cell — and one of the most directly impacted by NAD+ decline.
What Human Clinical Trials Show
Animal studies on NAD+ are extensive and compelling. But what do human trials tell us? More than is commonly acknowledged — though with important caveats.
NAD+ Precursor Supplementation (NMN and NR)
The most rigorous human data comes from oral and IV precursor supplementation rather than direct NAD+ injection. Key findings from published trials include:
- Yoshino et al. (2021, Science): NMN supplementation (250 mg/day, 10 weeks) in postmenopausal women with prediabetes improved skeletal muscle insulin sensitivity and increased levels of NAD+ metabolites in muscle tissue — the first human trial to demonstrate tissue-level NAD+ augmentation with oral supplementation.
- Martens et al. (2018, Nature Communications): NR supplementation (1,000 mg/day, 6 weeks) in healthy middle-aged and older adults increased circulating NAD+ metabolites by ~60% and modestly improved blood pressure and arterial stiffness markers.
- Dollerup et al. (2018, Nature Communications): NR supplementation did not improve insulin sensitivity in obese men in a 12-week randomized trial — a sobering result that suggests metabolic benefits may be population-dependent.
Direct Injectable NAD+
Human trial data on injectable NAD+ (IV or subcutaneous) is more limited, with most evidence coming from clinical observation and smaller trials rather than large randomized studies. The IV administration route bypasses absorption barriers and delivers NAD+ directly to the bloodstream, but it also means the infused NAD+ must be taken up by cells and converted into usable forms — a process that varies by tissue type.
Clinically, IV NAD+ has shown consistent subjective improvements in energy, mental clarity, and mood across multiple clinical series — though distinguishing pharmacological effects from placebo effects requires controlled study design that has not yet been applied at scale to the IV route specifically.
What We Can Reasonably Conclude
Based on the current published literature, the following conclusions appear supported by evidence:
- NAD+ levels in human tissue decline meaningfully with age, and this decline is mechanistically linked to impaired mitochondrial function, reduced sirtuin activity, and compromised DNA repair
- Oral NAD+ precursors (NMN, NR) can meaningfully increase circulating NAD+ metabolite levels in humans
- The downstream functional benefits in humans (improved insulin sensitivity, cardiovascular markers) are real but modest and population-dependent in published trials
- Animal longevity data is compelling but does not translate directly to human longevity claims
- Injectable NAD+ has a plausible mechanism for superior tissue delivery compared to oral precursors, but robust controlled human trial data specifically on injectable routes remains limited